Alcohol Addiction-Pipeline Review, H1 2015

Alcohol Addiction-Pipeline Review, H1 2015

  • Products Id :- GMDHC6149IDB
  • |
  • Pages: 119
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Alcohol Addiction-Pipeline Review, H1 2015


Global Markets Direct's, 'Alcohol Addiction-Pipeline Review, H1 2015', provides an overview of the Alcohol Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcohol Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Alcohol Addiction and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Alcohol Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Alcohol Addiction pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Alcohol Addiction Overview 10

Therapeutics Development 11

Pipeline Products for Alcohol Addiction-Overview 11

Pipeline Products for Alcohol Addiction-Comparative Analysis 12

Alcohol Addiction-Therapeutics under Development by Companies 13

Alcohol Addiction-Therapeutics under Investigation by Universities/Institutes 16

Alcohol Addiction-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Alcohol Addiction-Products under Development by Companies 20

Alcohol Addiction-Products under Investigation by Universities/Institutes 22

Alcohol Addiction-Companies Involved in Therapeutics Development 23

AbbVie Inc. 23

Addex Therapeutics Ltd 24

Adial Pharmaceuticals, LLC 25

Astraea Therapeutics, LLC 26

AstraZeneca PLC 27

Bionex Pharmaceuticals LLC 28

Curemark, LLC 29

D&A Pharma SAS 30

Eli Lilly and Company 31

Euthymics Bioscience, Inc. 32

Foresee Pharmaceuticals, LLC 33

Heptares Therapeutics Ltd. 34

Johnson & Johnson 35

Kyorin Pharmaceutical Co., Ltd. 36

Lohocla Research Corporation 37

Omeros Corporation 38

Pfizer Inc. 39

SK Biopharmaceuticals Co., Ltd. 40

Sun Pharma Advanced Research Company Ltd. 41

Tekmira Pharmaceuticals Corp. 42

Tonix Pharmaceuticals Holding Corp. 43

VM Discovery, Inc. 44

Zynerba Pharmaceuticals, Inc. 45

Alcohol Addiction-Therapeutics Assessment 46

Assessment by Monotherapy Products 46

Assessment by Combination Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

(disulfiram + selegiline)-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

(topiramate + ondansetron hydrochloride)-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

ABT-436-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

ADX-71441-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

amitifadine-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Antisense Gene Therapy for Alcoholism-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

baclofen ER-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

carisbamate-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

CM-1212-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Drug to Inhibit Triple Reuptake for Alcohol Dependence-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Drugs to Activate HAT for CNS Disorders-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Drugs to Inhibit Histone Deacetylase for CNS Disorders-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

FP-007-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

GET-73-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

ibudilast-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

JNJ-31020028-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

JNJ-5234801-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

LY-2940094-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

naltrexone-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

naltrexone-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

OMS-405-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

OMS-527-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

ondansetron hydrochloride-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

PF-04457845-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

saracatinib difumarate-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

SLV-330-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Small Molecule for Central Nervous System-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Small Molecule to Antagonize Ghrelin for Alcoholism-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Small Molecules to Agonize NOP for Pain-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

sodium oxybate IR-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

TKM-ALDH2-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

VMD-2202-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Alcohol Addiction-Recent Pipeline Updates 97

Alcohol Addiction-Dormant Projects 106

Alcohol Addiction-Discontinued Products 108

Alcohol Addiction-Product Development Milestones 109

Featured News & Press Releases 109

Jan 07, 2015: Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder 109

Apr 30, 2014: ADial Pharmaceuticals Announces Issuance of First U.S. Patent 109

Nov 04, 2013: Clinical Trial Indicates Gabapentin Is Safe and Effective for Treating Alcohol Dependence 110

Oct 10, 2013: Tekmira Provides Corporate Update on TKM-ALDH2 112

Aug 25, 2013: National Institute on Alcohol Abuse and Alcoholism Funds New UCLA Clinical Trial of MediciNova's MN-166 in Treating Alcoholism 113

Aug 12, 2013: ADial Pharmaceuticals Announces Publication of Study on AD04 for the Treatment of Patients With Alcohol Use Disorder 113

Aug 09, 2013: Curemark wins patent for CM-1212 to treat drug, alcohol addiction 114

May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441 115

Apr 30, 2013: Addex Therapeutics Reports ADX71441 Reduces Alcohol Intake In Preclinical Model Of Chronic Alcohol Dependence 115

Apr 18, 2013: ADial Pharma Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes 116

Appendix 118

Methodology 118

Coverage 118

Secondary Research 118

Primary Research 118

Expert Panel Validation 118

Contact Us 118

Disclaimer 119

List of Tables

Number of Products under Development for Alcohol Addiction, H1 2015 11

Number of Products under Development for Alcohol Addiction-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Development, H1 2015 19

Products under Development by Companies, H1 2015 20

Products under Development by Companies, H1 2015 (Contd..1) 21

Products under Investigation by Universities/Institutes, H1 2015 22

Alcohol Addiction-Pipeline by AbbVie Inc., H1 2015 23

Alcohol Addiction-Pipeline by Addex Therapeutics Ltd, H1 2015 24

Alcohol Addiction-Pipeline by Adial Pharmaceuticals, LLC, H1 2015 25

Alcohol Addiction-Pipeline by Astraea Therapeutics, LLC, H1 2015 26

Alcohol Addiction-Pipeline by AstraZeneca PLC, H1 2015 27

Alcohol Addiction-Pipeline by Bionex Pharmaceuticals LLC, H1 2015 28

Alcohol Addiction-Pipeline by Curemark, LLC, H1 2015 29

Alcohol Addiction-Pipeline by D&A Pharma SAS, H1 2015 30

Alcohol Addiction-Pipeline by Eli Lilly and Company, H1 2015 31

Alcohol Addiction-Pipeline by Euthymics Bioscience, Inc., H1 2015 32

Alcohol Addiction-Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 33

Alcohol Addiction-Pipeline by Heptares Therapeutics Ltd., H1 2015 34

Alcohol Addiction-Pipeline by Johnson & Johnson, H1 2015 35

Alcohol Addiction-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 36

Alcohol Addiction-Pipeline by Lohocla Research Corporation, H1 2015 37

Alcohol Addiction-Pipeline by Omeros Corporation, H1 2015 38

Alcohol Addiction-Pipeline by Pfizer Inc., H1 2015 39

Alcohol Addiction-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 40

Alcohol Addiction-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 41

Alcohol Addiction-Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 42

Alcohol Addiction-Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 43

Alcohol Addiction-Pipeline by VM Discovery, Inc., H1 2015 44

Alcohol Addiction-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 45

Assessment by Monotherapy Products, H1 2015 46

Assessment by Combination Products, H1 2015 47

Number of Products by Stage and Target, H1 2015 49

Number of Products by Stage and Mechanism of Action, H1 2015 51

Number of Products by Stage and Route of Administration, H1 2015 53

Number of Products by Stage and Molecule Type, H1 2015 55

Alcohol Addiction Therapeutics-Recent Pipeline Updates, H1 2015 97

Alcohol Addiction-Dormant Projects, H1 2015 106

Alcohol Addiction-Dormant Projects (Contd..1), H1 2015 107

Alcohol Addiction-Discontinued Products, H1 2015 108

List of Figures

Number of Products under Development for Alcohol Addiction, H1 2015 11

Number of Products under Development for Alcohol Addiction-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Products, H1 2015 19

Assessment by Monotherapy Products, H1 2015 46

Assessment by Combination Products, H1 2015 47

Number of Products by Top 10 Targets, H1 2015 48

Number of Products by Stage and Top 10 Targets, H1 2015 48

Number of Products by Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Top 10 Routes of Administration, H1 2015 52

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 52

Number of Products by Top 10 Molecule Types, H1 2015 54

Number of Products by Stage and Top 10 Molecule Types, H1 2015 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AbbVie Inc.

Addex Therapeutics Ltd

Adial Pharmaceuticals, LLC

Astraea Therapeutics, LLC

AstraZeneca PLC

Bionex Pharmaceuticals LLC

Curemark, LLC

D&A Pharma SAS

Eli Lilly and Company

Euthymics Bioscience, Inc.

Foresee Pharmaceuticals, LLC

Heptares Therapeutics Ltd.

Johnson & Johnson

Kyorin Pharmaceutical Co., Ltd.

Lohocla Research Corporation

Omeros Corporation

Pfizer Inc.

SK Biopharmaceuticals Co., Ltd.

Sun Pharma Advanced Research Company Ltd.

Tekmira Pharmaceuticals Corp.

Tonix Pharmaceuticals Holding Corp.

VM Discovery, Inc.

Zynerba Pharmaceuticals, Inc.

Alcohol Addiction Therapeutic Products under Development, Key Players in Alcohol Addiction Therapeutics, Alcohol Addiction Pipeline Overview, Alcohol Addiction Pipeline, Alcohol Addiction Pipeline Assessment

select a license

Single User License
USD 2000 INR 136600
Site License
USD 4000 INR 273200
Corporate User License
USD 6000 INR 409800



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]